On March 22, 2022 Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, reported that Company’s Management will provide a corporate update and participate in a panel discussion entitled "Pancreatic Cancer: Turning the Tide for One of the Most Challenging Indications in Oncology," at the Maxim 2022 Virtual Growth Conference, to be held virtually March 28-March 30, 2022 (Press release, Synthetic Biologics, MAR 22, 2022, View Source [SID1234610749]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the panel discussion include:

Title: "Pancreatic Cancer: Turning the Tide for One of the Most Challenging Indications in Oncology"

Date: March 28, 2022

Time: 12:00 p.m. – 1:00 p.m. ET

The conference will be available through the M-Vest portal for registered members.